LivaNova PLC (NASDAQ:LIVN) Given Consensus Recommendation of “Buy” by Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have earned a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $69.17.

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group assumed coverage on LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price target on the stock. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Robert W. Baird boosted their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Mizuho dropped their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Finally, StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

Several institutional investors and hedge funds have recently modified their holdings of LIVN. Canada Pension Plan Investment Board purchased a new position in shares of LivaNova in the second quarter valued at about $88,000. Central Pacific Bank Trust Division bought a new stake in LivaNova during the 3rd quarter valued at approximately $178,000. TradeLink Capital LLC purchased a new position in LivaNova in the 2nd quarter worth approximately $208,000. Captrust Financial Advisors bought a new position in LivaNova in the 3rd quarter worth approximately $217,000. Finally, Sanctuary Advisors LLC bought a new position in LivaNova in the 3rd quarter worth approximately $219,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Stock Down 1.1 %

Shares of NASDAQ LIVN opened at $46.56 on Friday. The business has a 50-day moving average of $50.93 and a 200-day moving average of $50.82. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.53 billion, a price-to-earnings ratio of 110.86 and a beta of 0.98. LivaNova has a 12 month low of $43.15 and a 12 month high of $64.47.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.